# A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia

> **NCT06874010** · PHASE1,PHASE2 · RECRUITING · sponsor: **Design Therapeutics, Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Friedreich Ataxia

## Interventions

- **DRUG:** DT-216P2

## Key facts

- **NCT ID:** NCT06874010
- **Lead sponsor:** Design Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06
- **Primary completion:** 2026-12
- **Final completion:** 2027-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06874010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06874010, "A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06874010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*